Pyrazine

Pyrazine

SCHEMBL306074

NC(=O)O.c1cnccn1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.54
NAPRT Q6XQN6 3/20 0.43
TSHR P16473 2/20 0.42
ADORA3 P0DMS8 2/20 0.42
MC4R P32245 1/20 0.42
ADRA1A P35348 1/20 0.42
MC3R P41968 1/20 0.42
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
SARM1 Q6SZW1 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
SIRT6 Q8N6T7 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
SIRT3 Q9NTG7 1/20 0.40
SIRT5 Q9NXA8 1/20 0.40
SIRT4 Q9Y6E7 1/20 0.40
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
HCAR2 Q8TDS4 2/20 0.38
MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrazine SCHEMBL4712089 1.00 ACHE (0.54) ACHENAPRTTSHRADORA3MC4R
Pyrazine SCHEMBL28327835 0.88 ALDH1A1 (0.50) ACHENAPRTTSHRADORA3MC4R
Oxamate SCHEMBL10805693 0.86 LDHA (0.60) ACHENAPRTTSHRADORA3MC4R
Oxamate SCHEMBL11103998 0.86 LDHA (0.60) ACHENAPRTTSHRADORA3MC4R
Pyridine SCHEMBL9065525 0.86 NAPRT (0.60) ACHENAPRTTSHRF7F3
Pyridine SCHEMBL1164077 0.86 NAPRT (0.60) ACHENAPRTTSHRF7F3
Pyrazine SCHEMBL27860453 0.84 NAPRT (0.47) NAPRTTSHRADORA3MC4RADRA1A
Pyridine SCHEMBL27840495 0.83 NAPRT (0.56) ACHENAPRTTSHRF7F3
Oxalic Acid SCHEMBL27623456 0.80 NAPRT (0.45) NAPRTTSHRADORA3MC4RADRA1A
Pyridine SCHEMBL1070164 0.79 NAPRT (0.60) ACHENAPRTTSHRADORA3F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3983072-A1 PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 EP disclosed
EP-3983072-A1 PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 EP disclosed
CN-113950357-A Pyrazine carbamates and their use as GluN2B receptor modulators 詹森药业有限公司 2022-01-18 CN disclosed
CN-113950357-A Pyrazine carbamates and their use as GluN2B receptor modulators 詹森药业有限公司 2022-01-18 CN disclosed
WO-2020249796-A1 PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 WO disclosed
US-20200392155-A1 PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 US disclosed
WO-2020249796-A1 PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 WO disclosed
US-20170267895-A9 POLISHING SLURRY FOR CMP AND POLISHING METHOD HITACHI CHEMICAL COMPANY, LTD. (JP) 2017-09-21 US disclosed
US-20150315419-A1 POLISHING SLURRY FOR CMP AND POLISHING METHOD HITACHI CHEMICAL COMPANY, LTD. (JP) 2015-11-05 US disclosed
US-20140065825-A1 POLISHING SLURRY FOR CMP AND POLISHING METHOD HITACHI CHEMICAL CO., LTD. (JP) 2014-03-06 US disclosed
US-20090143357-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 ICOS CORPORATION (US) 2009-06-04 US disclosed
EP-1936673-A1 POLISHING SOLUTION FOR CMP AND METHOD OF POLISHING Hitachi Chemical Co., Ltd. (JP) 2008-06-25 EP disclosed
EP-1869020-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl ICOS Corporation (US) 2007-12-26 EP disclosed
US-20070117394-A1 Polishing slurry for CMP and polishing method HITACHI CHEMICAL CO., LTD. (JP) 2007-05-24 US disclosed
WO-2006105262-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl ICOS CORPORATION (US) 2006-10-05 WO disclosed
US-6706732-B1 PROPHYLACTIC AND THERAPEUTIC EFFECT ON MYOCARDIAL INFARCTION AND ACCOMPANYING DYSFUNCTIONS, ARRHYTHMIA, UNSTABLE ANGINA, CARDIAC HYPERTROPHY, ETC.; SODIUM-PROTON EXCHANGE INHIBITION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-16 US disclosed
EP-0803502-B1 Process for the preparation of optically active piperazine-2-carboxylic acid derivatives LONZA AG (CH) 2002-06-26 EP disclosed
EP-1182194-A1 PERNASAL PREPARATIONS Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed
EP-0803502-A2 Process for the preparation of optically active piperazine-2-carboxylic acid derivatives LONZA AG (CH) 1997-10-29 EP disclosed
EP-0537937-A2 Substituted pyrazino 2,3-D pyrimidinones as angiotensin II antagonists MERCK & CO. INC. (US) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392155-A1 PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ACHE 793/4885NAPRT 588/4885TSHR 445/4885
US-20090143357-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 CHEK1, CHEK2, PCNA ACHE 2611/4885NAPRT 1952/4885TSHR 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.